Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 6/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | RECQL | P46063 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.33 |
| ▸ | HTR3B | O95264 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5881155 | 0.75 | ALDH1A1 (0.50) | ALDH1A1TSHRCYP3A4HSD17B10RECQL | |
| SCHEMBL4634658 | 0.75 | ALDH1A1 (0.50) | ALDH1A1TSHRCYP3A4HSD17B10RECQL | |
| SCHEMBL3185565 | 0.75 | ALDH1A1 (0.50) | ALDH1A1TSHRCYP3A4HSD17B10RECQL | |
| SCHEMBL18698310 | 0.71 | ALDH1A1 (0.45) | ALDH1A1TSHRCYP3A4HSD17B10RECQL | |
| SCHEMBL11240308 | 0.71 | ALDH1A1 (0.45) | ALDH1A1TSHRCYP3A4HSD17B10RECQL | |
| SCHEMBL6378876 | 0.71 | CYP1A2 (0.43) | ALDH1A1TSHRCYP3A4HTR3EHTR3B | |
| SCHEMBL11883606 | 0.70 | HTR3E (0.56) | ALDH1A1TSHRCYP3A4HSD17B10RECQL | |
| SCHEMBL8107432 | 0.67 | ALDH1A1 (0.41) | ALDH1A1TSHRCYP3A4HSD17B10RECQL | |
| SCHEMBL2937097 | 0.66 | TSHR (0.67) | ALDH1A1TSHRCYP3A4HSD17B10RECQL | |
| SCHEMBL6139486 | 0.65 | ALDH1A1 (0.42) | ALDH1A1TSHRCYP3A4HSD17B10RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114057672-B | Qionanol derivative | 山东省医学科学院药物研究所（山东省抗衰老研究中心、山东省新技术制药研究所） | 2023-10-17 | — | — | CN | claimed |
| CN-114057672-A | Kirenol derivatives | 山东省医学科学院药物研究所（山东省抗衰老研究中心、山东省新技术制药研究所） | 2022-02-18 | — | — | CN | claimed |
| US-7098215-B2 | Nitrogenous compounds and antiviral drugs containing the same | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 2006-08-29 | — | — | US | claimed |
| EP-1066269-B1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2005-05-11 | — | — | EP | claimed |
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | DAEYAERT FREDERIK FRANS DESIRE (BE) | 2002-08-22 | — | — | US | claimed |
| EP-1066269-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-10 | — | — | EP | claimed |
| US-6150360-A | ADMINISTERING TO A PATIENT SUFFERING FROM HUMAN IMMUNODEFICIENCY VIRUS INFECTION A TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVE | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-11-21 | — | — | US | claimed |
| WO-1999050256-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-10-07 | — | — | WO | claimed |
| CN-114057672-B | Qionanol derivative | 山东省医学科学院药物研究所（山东省抗衰老研究中心、山东省新技术制药研究所） | 2023-10-17 | — | — | CN | disclosed |
| CN-114057672-A | Kirenol derivatives | 山东省医学科学院药物研究所（山东省抗衰老研究中心、山东省新技术制药研究所） | 2022-02-18 | — | — | CN | disclosed |
| EP-1066269-B1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2005-05-11 | — | — | EP | disclosed |
| US-6774235-B2 | HAVING HIV REPLICATION INHIBITING PROPERTIES. | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-10 | — | — | US | disclosed |
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | DAEYAERT FREDERIK FRANS DESIRE (BE) | 2002-08-22 | — | — | US | disclosed |
| US-6372729-B1 | TREATMENT OF VIRAL DISEASES SUCH AS AIDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-04-16 | — | — | US | disclosed |
| EP-1066269-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-10 | — | — | EP | disclosed |
| US-6150360-A | ADMINISTERING TO A PATIENT SUFFERING FROM HUMAN IMMUNODEFICIENCY VIRUS INFECTION A TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVE | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-11-21 | — | — | US | disclosed |
| WO-1999050256-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | XDH, CCR5, CXCR1 | ALDH1A1 3722/4885TSHR 656/4885CYP3A4 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.